Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
  • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1825—Fibroblast growth factor [FGF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1841—Transforming growth factor [TGF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
  • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/54—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
  • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/412—Tissue-regenerating or healing or proliferative agents
  • A61L2300/414—Growth factors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2430/00—Materials or treatment for tissue regeneration
  • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

• the present invention relates to new indications for a certain class of drugs. More specifically, the present invention relates to the use of bisphosphonates in the treatment of osteonecrosis and related disorders such as osteochondritis dissecans. In a further disclosure, the invention relates to the use of bisphosphonates in the management of patients at risk of developing osteonecrosis. Backfiround of the Invention
• Osteonecrosis is a distinct clinical and pathological entity, with many different causes and differing pathogeneses. Although much has been written about the disorder, all the factors in the aetiology and pathogenesis are not known at this time. Osteonecrosis can affect an area spontaneously in adults and children (Perthes disease), or result from such disease processes as alcoholism, exposure to glucocorticoids and or cytotoxic drugs, exposure to a hyperbaric environment (caisson disease) 1 , fracture, infection, haematological disease, to name some examples. No proven pharmacological agent is currently available for the treatment of osteonecrosis.
• osteonecrosis usually affects the function of a joint and most commonly the hip joint. If the hip joint is affected, the femoral head is susceptible to collapse, leading to pain, stiffness and long-term disability. The affected joint is further susceptible to deformity and osteoarthritis. Osteonecrosis having unknown aetiology affects a significant percentage of the population including children. Particularly, Perthes disease (Legg-Calve-Perthes disease) is common, with an incidence of 8.5 to 21 per 100,000 children per annum u m ⁇ v v .
• Osteonecrosis also occurs in patients who are recovering from bone marrow, kidney, lung and liver transplantation xv ⁇ v ⁇ vm ' lx ⁇ Children who sustain a fracture of the neck of the femur can also go on to suffer from osteonecrosis of the femoral head, as can children with slipped upper femoral epiphysis. The outcome in patients is often poor if they develop avascular necrosis'TM. In a recent study of femoral neck fracture in children, avascular necrosis occurred in 40% XX1 .
• Surgical solutions for osteonecrosis include core decompression to reduce the intraosseous pressure and increase new blood supply; bone grafting, either through the core decompression or through the joint (trapdoor procedure); vascularised bone and/or tissue transplantation; and redirectional osteotomy of the affected segment away from load.
• Containment treatment in Perthes disease either non-operative or operative, in an attempt to reshape the collapsed femoral head, is well described.
• the use of an external fixator or brace to unload the joint and prevent collapse of the affected part is also well described.
• Surgical treatment of the related disease osteochondritis dissecans usually involves stabilising a fragment of subchondral bone which has become detached from the adjacent bone with a fixation device, with or without bone grafting and drilling of the bone. Sometimes excision of the fragment is required.
• the present invention consists in a drug selected from a group consisting of at least one bisphosphonate when used for the treatment of osteonecrosis.
• the present invention consists in a drug selected from a group consisting of at least one bisphosphonate when used for the treatment of osteochondritis dissecans.
• the invention consists in a method of treating a patient with osteonecrosis and/or osteochondritis dissecans, the method including the step of administering to the patient a drug selected from a group consisting of at least one bisphosphonate.
• the invention consists in a method of preventing osteonecrosis and/or osteochondritis dissecans and any complications associated with said diseases in a patient at risk of either of the diseases, the method including the step of administering to the patient a drug selected from the group consisting of at least one bisphosphonate.
• the invention consists in the use of a drug selected from a group consisting of at least one bisphosphonate for the manufacture of a medicament for the treatment of osteonecrosis.
• the invention consists in the use of a drug selected from a group consisting of at least one bisphosphonate for the manufacture of a medicament for the treatment of osteochondritis dissecans.
• the invention consists in the use of a drug selected from the group consisting of at least one bisphosphonate for the manufacture of a medicament suitable for prophylactic administration to a patient at risk of developing osteonecrosis and/or osteochondritis dissecans.
• the present invention consists in a drug selected from the group consisting of at least one bisphosphonate when used for the prevention of cartilage destruction or chondrolysis associated with osteonecrosis and/or osteochondritis dissecans.
• the present invention consists in a method of preventing cartilage destruction or chondrolysis associated with osteonecrosis and/or osteochondritis dissecans, the method including the step of administering to a patient a drug selected from the group consisting of at least one bisphosphonate.
• the selected bisphosphonate preferably acts to at least lessen or prevent the severity of deformity and/or collapse of bone and cartilage and permit new bone formation in the patient.
• such prophylactic administration preferably has the effect of creating a depot of therapeutically effective bisphosphonate within the body of the patient thereby minimising collapse and deformity of the bone and encouraging new bone formation, and maintenance of bone structure, should osteonecrosis occur.
• the drug is given intravenously.
• the drug may be given orally.
• the drug may be administered subcutaneously, intramuscularly, transdermally, topically or by any other route whence it can produce its therapeutic effect.
• the drug is administered locally to a target site.
• the drug may be administered locally during a surgical procedure for osteonecrosis.
• the drug may be administered by direct application to bone surfaces, or as part of a local delivery system.
• the local delivery system may take the form of a bone graft substitute or extender, or autogenous or allogenic bone graft.
• the bone graft substitute or extender may contain calcium sulphate, calcium carbonate, tricalcium phosphate, hydroxyapatite, or other calcium containing compounds, alone or in any combination.
• the bone graft substitute, extender, autograft or allograft may also contain, in addition to being admixed with an effective amount of bisphosphonate, a carrier medium such as collagen, gelatine, glycerol, propylene glycol, resin, polyglycolic acid (PGA), poly-1 lactic acid (PLLA), poly d-1 lactic acid (PLLA), porous silicon, or any other resorbable biocompatible medium, either in the form of injectable liquid, gel, putty or cement or in the form of mouldable liquid, cement, putty, gel, flexible sheets, mesh or sponge or other readily applicable method. It may also include any combination of above and any binding agent.
• the bisphosphonate and the carrier alone may also be used for local delivery.
• the carrier may contain nutrients required by cells involved in bone formation or other cells and is preferably resorbable.
• the carrier may further contain gene products known to be implicated in bone healing. Examples of suitable gene products include, but are not limited to, Bone Morphogenetic Protein 7 (OP-1), BMP-2 and -4, other bone morphogenetic proteins, transforming growth factor beta, fibroblast growth factor (basic or acidic), insulin-like growth factor -1 or -2, osteocalcin, or other known biologically active proteins, polypeptides, or gene products.
• OP-1 Bone Morphogenetic Protein 7
• BMP-2 and -4 other bone morphogenetic proteins
• transforming growth factor beta transforming growth factor beta
• fibroblast growth factor basic or acidic
• insulin-like growth factor -1 or -2 osteocalcin
• the carrier medium may also contain blood products containing growth factors or cells, "buffy coat" (for example AGFTM), bone marrow aspirate or cultured osteoblastic cells or precursors, or multipotential stem cells.
• the carrier may also contain cells transfected with bone formation genes, for example via an adenoviral vector, such that they overexpress genes implicated in bone healing, leading to increased bone formation.
• a number of combination of cells, gene product growth factors, nutrients, carrier medium and bone graft substitute may prove efficacious when admixed with at least one bisphosphonate.
• the drug is zoledronic acid (zoledronate) ⁇ 1- hydroxy-2-[(lH-imidazol-l-yl)ethylidine] bisphosphonic acid ⁇ .
• the drug may be pamidronate ⁇ 3-amino-l-hydroxypropylidene bisphosphonic acid ⁇ , alendronate ⁇ 4-amino-l- hydroxybutylidene bisphosphonic acid ⁇ , etidronate ⁇ 1-hydroxyethylidene bisphosphonic acid ⁇ , clodronate ⁇ dichloromethylene bisphosphonic acid ⁇ , risedronate ⁇ 2-(3-pyridinyl)-l- hydroxyethylidene bisphosphonic acid ⁇ , tiludronate ⁇ chloro-4- phenylthiomethylidene bisphosphonic acid ⁇ , ibandronate ⁇ 1-hydroxy- 3(methylpentylamino)-propylidene bisphosphonic acid ⁇ , incadronate ⁇
• the osteonecrosis or osteochondritis dissecans affects the femoral head, distal femur, proximal tibia, talus, navicular or other tarsal bone, metatarsal head, humeral head or proximal humerus, capitellum or distal humerus, radial head, scaphoid, lunate or other carpal bone. It is envisaged, however, that the disease may affect any other bone or joint within the body of a patient.
• the osteonecrosis presents in a child diagnosed with Perthes disease (Legg-Calve-Perthes disease).
• the osteonecrosis or osteochondritis may be of unknown cause.
• the osteonecrosis or osteochondritis dissecans may develop secondary to a disease process.
• the osteonecrosis or osteochondritis dissecans may be secondary to disease such as Gaucher's disease, sickle cell disease or other haematological disorder, renal failure, liver failure, endocrine disorder, HIN and associated syndromes, leukaemia or other malignancy, primary bone dysplasia, connective tissue disorder, autoimmune disorder, or immunosuppression disorder.
• the osteonecrosis or osteochondritis dissecans may develop following exposure to substances known to be of high risk in causing osteonecrosis, including but not limited to corticosteroids (glucocorticoids), cyclosporin or other immune suppressant medications, cytotoxic drugs for malignancy or forms of rheumatoid arthritis, illicit substance abuse, alcohol abuse, and/or cigarette smoking.
• corticosteroids glucocorticoids
• cyclosporin or other immune suppressant medications cytotoxic drugs for malignancy or forms of rheumatoid arthritis
• illicit substance abuse alcohol abuse
• alcohol abuse and/or cigarette smoking.
• the osteonecrosis or osteochondritis dissecans may develop following a bone marrow transplant or organ transplant.
• the osteonecrosis or osteochondritis dissecans may be related to a trauma such as a fracture.
• the fracture may be of the femoral head, neck or intertrochanteric femoral fracture, fracture of the head or neck of the radius, capitellum of the humerus, fracture of the talus or other tarsal bone, fracture of the humeral head, neck or subcapital region in the shoulder, fracture of the scaphoid, lunate or other carpal bone.
• the fracture may be in some other bone.
• the osteonecrosis or osteochondritis dissecans may be related to an injury that is not a fracture, for example, a dislocation or subluxation.
• the drug may be administered to a patient perioperatively for osteonecrosis or osteochondritis dissecans.
• the surgery may involve core decompression, bone graft, vascularised bone or tissue graft or transfer, "trapdoor" bone grafting procedure, osteoplasty or chondroplasty, osteotomy, or internal or external fixation.
• the drug may be administered to a patient who is known to have previously suffered from osteonecrosis at one site, and who is therefore at high risk of developing osteonecrosis at another site.
• the known osteonecrosis may involve the femoral head, distal femur, proximal tibia, talus or other tarsal bone, metatarsal head, humeral head or proximal humerus, capitellum or distal humerus, radial head, scaphoid, lunate or other carpal bone.
• the drug may be administered prophylactically to patient who has suffered a fracture wherein there is a high risk of the fracture leading to osteonecrosis.
• the fracture may be of the femoral head, neck or intertrochanteric femoral fracture, a slipped capital femoral epiphysis or other epiphysis, fracture of the head or neck of the radius, capitellum of the humerus, fracture of the talus or other tarsal bone, fracture of the humeral head, neck or subcapital region in the shoulder, fracture of the scaphoid, lunate or other carpal bone.
• prophylactic treatment may be commenced on a patient who has suffered an injury that is not a fracture, for example, a dislocation or subluxation, wherein the injury has a risk of leading to osteonecrosis, for example, traumatic hip dislocation and traumatic shoulder dislocation.
• the drug may be administered prophylactically to a patient who is to undergo, is undergoing or has recently undergone, an operation known to be associated with osteonecrosis.
• the operation may involve reduction of a congenital or developmental dislocation of the hip, an osteotomy near any joint, an osteoplasty, core decompression or bone graft, vascularized bone or soft tissue transfer, "trapdoor” bone grafting procedure for the treatment of osteonecrosis.
• a further indication for prophylactic treatment may be in cases of osteonecrosis or osteochondritis dissecans secondary to a disease process such as Gaucher's disease, sickle cell disease or other haematological disorder, renal failure, liver failure, endocrine disorder, HIN and associated syndromes, leukaemia or other malignancy, primary bone dysplasia, connective tissue disorder, autoimmune disorder, or immunosuppression disorder.
• a disease process such as Gaucher's disease, sickle cell disease or other haematological disorder, renal failure, liver failure, endocrine disorder, HIN and associated syndromes, leukaemia or other malignancy, primary bone dysplasia, connective tissue disorder, autoimmune disorder, or immunosuppression disorder.
• the patient that is the subject of prophylactic treatment may have been exposed to substances known to be of high risk in causing osteonecrosis including but not limited to corticosteroids (glucocorticoids), cyclosporin or other immune suppressants, cytotoxic drugs for malignancy or forms of rheumatoid arthritis, illicit substance abuse, alcohol abuse, and/or cigarette smoking.
• substances known to be of high risk in causing osteonecrosis including but not limited to corticosteroids (glucocorticoids), cyclosporin or other immune suppressants, cytotoxic drugs for malignancy or forms of rheumatoid arthritis, illicit substance abuse, alcohol abuse, and/or cigarette smoking.
• the patient may be at high risk of developing osteonecrosis or osteochondritis dissecans following a bone marrow transplant or organ transplant.
• the drug of the present invention may be administered concurrently with a radiotherapy regime.
• the bisphosphonate may be zoledronic acid (zoledronate), or any pharmaceutically acceptable salt or ester thereof.
• the zoledronic acid is administered parenterally and preferably in a dose from about 0.25mg to about 12mg in an adult patient or about 0.005mg/kg to about 0.5mg/kg in a child, approximately every three months.
• the zoledronic acid may be administered four-weekly, six-weekly or every two months.
• the zoledronic acid may be administered as a single dose and further doses administered if required.
• the zoledronic acid may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, approximately every three months.
• the zoledronic acid may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, approximately every six months.
• the zoledronic acid may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, approximately every twelve months.
• the zoledronic acid may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, as a single dose.
• the zoledronic acid may be given orally.
• the bisphosphonate is pamidronate or any pharmaceutically acceptable salt or ester thereof.
• the pamidronate is administered parenterally and preferably in a dose from about 15 to about 90mg approximately every one to three months in an adult patient or 0.25mg/kg to 3.0mg/kg every one to three months in a child.
• the pamidronate may be administered parenterally in a dose of about 15mg, about 30mg, about 60mg or about 90mg every one to three months in an adult patient or 0.25mg/kg, about 0.5mg/kg, about l.Omg/kg, about 2.0mg /kg or about 3.0mg/kg every one to three months in a child.
• pamidronate is administered parenterally in a dose of about 15 mg, about 30mg about 60mg or about 90mg approximately every six months in an adult patient or 0.25mg/kg, about 0.5mg/kg, about l.Omg/kg, about 2.0mg /kg or about 3.0mg/kg approximately every six months in a child.
• pamidronate is administered parenterally in a dose of about 15 mg, about 30mg, about 60mg or about 90mg approximately every twelve months in an adult patient or 0.25mg/kg, about 0.5mg/kg, about l.Omg/kg, about 2.0mg /kg or about 3.0mg/kg approximately every twelve months in a child.
• pamidronate is administered parenterally in a dose of about 15mg, about 30mg, about 60mg, or about 90mg in an adult patient or 0.25mg/kg, about 0.5mg/kg, about l.Omg/kg, about 2.0mg /kg or about 3.0mg/kg in a child, as a single dose.
• the bisphosphonate is alendronate or any pharmaceutically acceptable salt or ester thereof.
• the alendronate is administered orally and preferably in a dose from about 2.5mg to about 50mg per day or about lOmg to about 300mg per week for an adult patient.
• the preferable oral dose is from about 0.05mg/kg to l.Omg/kg per day or about 0.2mg/kg to 6.0mg/kg per week.
• the alendronate may be administered orally in a dose of about 5mg, about lOmg, about 20mg or about 40 mg per day or about 35mg, about 70mg about 140mg or about 280 mg per week for an adult.
• the alendronate may be administered orally in a dose of about O.lmg/kg, about 0.2mg/kg, about 0.4mg/kg, or about 0.8mg/kg per day, or about 0.8mg/kg, about 1.5mg/kg, about 3.0mg/kg or about 5.0mg/kg per week.
• the alendronate is administered parenterally and preferably in a dose from about 0.25mg to about 30mg approximately every one to three months, or as a single dose.
• the bisphosphonate is risedronate or any pharmaceutically acceptable salt or ester thereof.
• the risedronate is administered orally and preferably in a dose from about 2.5mg to about 60mg per day or about lOmg to about 300mg per week in an adult patient or about 0.05mg/kg to about l.Omg/kg per day or about 0.25mg/kg to about 7.0mg/kg in a child.
• the risedronate may be administered orally in a dose of about 2.5mg, about 5mg, about lOmg or about 30mg per day, or aboutl ⁇ mg, about 30mg, about 60mg, or about 210mg per week in an adult patient or, for a child, about 0.05mg/kg, about O.lmg/kg, about 0.2mg/kg, about 0.5mg/kg per day, or about 0.25mg /kg, or about 0.5mg/kg, about l.Omg/kg, or about 2.5mg/kg per week.
• the Risedronate may be administered intravenously.
• the bisphosphonate is ibandronate or any pharmaceutically acceptable salt or ester thereof.
• the ibandronate is administered parenterally and preferably in a dose from about 0.25mg to about 30mg, and more preferably in a dose of about 2mg to 10 mg approximately every one to three months, or as a single dose.
• the ibandronate is given orally in a dose of about 2.5mg, about 5mg, about lOmg or about 30mg per day, or about 15 mg, about 30mg, about 60mg, or about 210mg per week in an adult patient or, for a child, about 0.05mg/kg, about O.lmg/kg, about 0.2mg/kg, about 0.5mg/kg per day, or about 0.25mg /kg, or about 0.5mg/kg, about l.Omg/kg, or about 2.5mg/kg per week.
• the bisphosphonate is incadronate or any pharmaceutically acceptable salt or ester thereof.
• the incadronate is administered parenterally and preferably in a dose from about 0.25mg to about 30mg, more preferably about lOmg in an adult patient or, for a child, from about 0.005 mg/kg to 0.6 mg/kg, more preferably about 0.025 mg/kg to 0.25 mg/kg approximately every one to three months, or as a single dose.
• the incadronate is given orally in a dose of about 2.5mg, about 5mg, about lOmg or about 30mg per day, or about 15 mg, about 30mg, about 60mg, or about 210mg per week in an adult patient or, for a child, about 0.05mg/kg, about O.lmg/kg, about 0.2mg/kg, about 0.5mg/kg per day, or about 0.25mg /kg, or about 0.5mg/kg, about l.Omg/kg, or about 2.5 mg/kg per week.
• the bisphosphonate is minodronate or any pharmaceutically acceptable salt or ester thereof.
• the minodronate is administered 0.25mg to about 30mg approximately every one to three months, or as a single dose. More preferably, the minodronate is administered parenterally and preferably in a dose from about 0.25mg to about 12mg in an adult patient or about 0.005mg/kg to about 0.5mg/kg in a child, approximately every three months.
• the minodronate may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075 mg/kg or about O.lmg/kg in a child, approximately every three months.
• the minodronate may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, approximately every six months.
• the minodronate may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, approximately every twelve months.
• the minodronate may be administered parenterally in a dose of about 2mg, about 4mg, about 6mg or about 8mg for an adult patient or about 0.025mg/kg, about 0.05mg/kg, about 0.075mg/kg or about O.lmg/kg in a child, as a single dose.
• the minodronate may be given orally.
• the bisphosphonate is clodronate or any pharmaceutically acceptable salt or ester thereof.
• the clodronate may be given orally in a dose range of about 400 mg to 2400mg per day in an adult or, for a child, 50 mg/kg to 250 mg/kg or administered intravenously in dose ranges from 150 mg to 300 mg or, for a child, 1 mg/kg to 5 mg/kg, repeated daily for 2 to 5 days, and repeated as necessary, possibly every one to six months.
• the bisphosphonate is etidronate or any pharmaceutically acceptable salt or ester thereof.
• the etidronate may be given orally in a dose range of about 100 to 400 mg (5 to 20 mg/kg per day) or, for a child, 5 to 20 mg/kg per day.
• the bisphosphonate is tiludronate or any pharmaceutically acceptable salt or ester thereof.
• the tiludronate may be given orally in a dose range of about 400 mg per day in an adult or, for a child, 5 to 20 mg/kg per day.
• the bisphosphonate is olpadronate or any pharmaceutically acceptable salt or ester thereof.
• the olpadronate may be given orally in a dose range of about 50-400 mg per day in an adult or, for a child, lmg/kg to 10 mg/kg or administered intravenously in dose ranges from lmg to 20 mg or, for a child, 0.1 mg/kg to 0.5 mg/kg, every one to three months.
• the bisphosphonate is neridronate or any pharmaceutically acceptable salt or ester thereof.
• the neridronate is given parenterally in a dose range from lOmg to 100 mg in an adult, or for a child, 0.1 to 2 mg/kg intravenously every one to three months.
• the drug is EB-1053.
• Fig. 1 is a generic formula for one class of bisphosphonates.
• Figs. 2A and 2B are radiographs of patients diagnosed with Perthes disease.
• Fig. 3 is a set of representative radiographs of the proximal femurs of the rats of Example 1.
• Fig. 4 is a set of X rays of the proximal femurs of each of the rats of Example 1.
• Fig. 5 is a set of TC 99 bone scans to show revascularisation of the proximal femurs of each of the rats of Example 1.
• Figure 6 is a set of Non Kossa undecalcified histology slides showing the preservation of bone architecture of the proximal femurs of the rats of Example 1.
• Figure 7 is a set of toluidine blue histology slides showing the preservation of articular cartilage in the rats of Example 1.
• Fig. 8 is a set of fluorescent histology slides showing bone formation activity in the proximal femurs of the groups of rats in Example 1.
• the invention relates to the use of a bisphosphonate with the following formula depicted in Fig. 1 wherein R t and R 2 are varied to give various potencies and other properties to the bisphosphonate.
• the present invention relates to a novel pharmacological treatment for osteonecrosis, including osteonecrosis affecting bone and cartilage adjacent to a joint.
• a therapeutically effective dose of at least one bisphosphonate, such as zoledronic acid the collapse of the necrotic bone can be slowed due to decreased osteoclast activity, while increases in the mineralisation of new bone may speed up the reparative process with new bone of improved mechanical integrity, thereby reducing the magnitude of any collapse of the affected bone and cartilage. This minimises the risk of deformity of the joint or bone and, further, reduces the risk of pain and the development of osteoarthritis.
• Radiograph (A) shows the hip joint of a 7 year old boy diagnosed with Perthes disease six months prior to the taking of the X-ray.
• Radiograph (B) shows the hip joint of a second boy diagnosed with Perthes disease twelve months prior to the taking of the X-ray.
• the epiphysis (growing femoral head) 10 is clearly necrotic.
• the highly mineralised bone in the necrotic epiphysis is being resorbed in response to various endogenous mediators, such that its mechanical integrity is breached, and it is collapsing.
• a model of traumatic osteonecrosis was utilised in 24 female 14-week - old Wistar rats. The animals were followed for six weeks after an operation designed to disrupt the blood supply to the femoral head. The six week time point was chosen as a time point when femoral head collapse is known to have occurred in this model ⁇ Animal ethics approval was received. Rats were randomised in lots of 4 into three groups according to the schedule below. Controls receive only saline (S) injections via a subcutaneous route. Post-treated animals received saline only pre- operatively, but zoledronic acid (ZA) (Novartis) 0.1 mg/kg, from commercial stock, was administered by subcutaneous injection post-operatively at 1 and 4 weeks. Pre and Post-treated animals received zoledronic acid 0.1 mg/kg at all three time points.
• S saline
• ZA zoledronic acid
• Dual fluorescent labels were applied at weeks 4 and 5: at week 4 demeclocycline 30 mg/kg was administered intraperitoneally, and at week 5 calcein 20mg/kg was administered intraperitoneally. One hour prior to culling 70 MBq Tc99 MDP was administered subcutaneously to allow bone scintigraphy to be performed on harvested specimens.
• Specimens were resin embedded and sectioned undecalcified. Coronal sections (6 microns) were cut through the femoral head. Sections were stained with von Kossa to assess trabecular bone volume and structure. Fluorescent microscopy was used on unstained sections to image the fluorescent labels and assess bone formation.
• the femoral heads in the saline group were smaller as a percentage of the non-operated side as measured by the Bioquant image analysis system (Table I).
• the femoral heads of the operated saline group were reduced to 63% of the contralateral (non-operated hip). This effect was significantly reduced when both treated groups were compared to the saline treated non- operated controls (p ⁇ 0.01, ANOVA).
• the greatest preservation of the femoral head was in the pre-post treated group (85%), but the post treated group (79%) was still significantly better preserved than controls (p ⁇ 0.01, t test).
• DEXA scans showed a significant increase (P ⁇ 0.01, ANOVA) in femoral head BMD and BMC for treated over control groups, with preservation of values at or near non-operated controls (Table II).
• strength correlates well with BMC, which was reduced to nearly one third in the saline group.
• Bone scintigraphy showed complete revascularisation, the operated side producing increased uptake over the non-operated side in all cases as shown in Fig 5.
• the top row were in saline group
• the second row were in the post-treated group
• the third row were in the pre and post-treated group.
• Right hips were operated on and left were not.
• Histology showed preservation of bone architecture in both treated groups, whereas the operated controls had resorbed much of the epiphysis, and it was broad and flat (Fig 6).
• Pre-post treated animals (bottom right) had definite but lesser amount of bone formation between weeks 4 and 5, with very few surfaces on which to form bone as it was so densely packed. There was no evidence of bone formation at the physis in the operated specimens. Discussion Administration of zoledronic acid reduced epiphyseal destruction (anti- resorptive effect) but also allowed new bone formation and mineralisation leading to a viable, preserved epiphysis. Articular cartilage preservation was also evident in treated groups. The femoral necks were partially resorbed in the post treated group. It is assumed that this occurred in the week prior to zoledronic acid administration, as this was not present to the same degree in the pre and post group.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Cell Biology (AREA)
• Molecular Biology (AREA)
• Developmental Biology & Embryology (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Biotechnology (AREA)
• Virology (AREA)
• Dermatology (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Pain & Pain Management (AREA)
• Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (21)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=27158265

Family Applications (1)

Country Status (23)

Cited By (6)

Families Citing this family (22)

Citations (5)

Family Cites Families (14)

• 2001
  • 2001-12-13 AT AT01273650T patent/ATE496624T1/de active
  • 2001-12-13 CZ CZ20032408A patent/CZ301361B6/cs not_active IP Right Cessation
  • 2001-12-13 JP JP2002562358A patent/JP2004527479A/ja active Pending
  • 2001-12-13 CA CA2435552A patent/CA2435552C/en not_active Expired - Fee Related
  • 2001-12-13 PL PL36190901A patent/PL361909A1/xx not_active IP Right Cessation
  • 2001-12-13 KR KR10-2003-7010328A patent/KR20030072399A/ko not_active Ceased
  • 2001-12-13 WO PCT/AU2001/001616 patent/WO2002062351A1/en not_active Ceased
  • 2001-12-13 MX MXPA03007029A patent/MXPA03007029A/es active IP Right Grant
  • 2001-12-13 US US10/470,924 patent/US7425549B2/en not_active Expired - Fee Related
  • 2001-12-13 DK DK01273650.0T patent/DK1365769T3/da active
  • 2001-12-13 AU AU2002221339A patent/AU2002221339B2/en not_active Ceased
  • 2001-12-13 NZ NZ527351A patent/NZ527351A/en not_active IP Right Cessation
  • 2001-12-13 EP EP01273650A patent/EP1365769B1/en not_active Expired - Lifetime
  • 2001-12-13 SI SI200130991T patent/SI1365769T1/sl unknown
  • 2001-12-13 DE DE60143964T patent/DE60143964D1/de not_active Expired - Lifetime
  • 2001-12-13 BR BR0116862-2A patent/BR0116862A/pt not_active Application Discontinuation
  • 2001-12-13 HU HU0303013A patent/HUP0303013A3/hu unknown
  • 2001-12-13 SK SK986-2003A patent/SK9862003A3/sk unknown
  • 2001-12-13 CN CNB018225365A patent/CN1233325C/zh not_active Expired - Fee Related
• 2003
  • 2003-07-30 ZA ZA2003/05890A patent/ZA200305890B/en unknown
  • 2003-07-31 IL IL157201A patent/IL157201A/en not_active IP Right Cessation
  • 2003-08-04 NO NO20033446A patent/NO20033446L/no not_active Application Discontinuation
• 2008
  • 2008-08-13 US US12/191,264 patent/US7612050B2/en not_active Expired - Fee Related
• 2011
  • 2011-04-20 CY CY20111100406T patent/CY1111402T1/el unknown

Patent Citations (5)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events